


WHAT IS CLAIMED IS:


- 1 1. A compound 3-(3,5-difluorophenyl)-2-[4-[(*E*)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2*H*-chromen-7-ol represented by Formula I:



Formula I

3
4 or a pharmaceutically acceptable salt thereof.

- 1 2. A compound (2*S*)-3-(3,5-difluorophenyl)-2-[4-[(*E*)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2*H*-chromen-7-ol represented by Formula Ia:



Formula Ia

3
4 or a pharmaceutically acceptable salt thereof.

- 1 3. A pharmaceutical composition comprising a compound of claim 1 and a
2 pharmaceutically acceptable carrier, diluent, or excipient.


- 1 4. A pharmaceutical composition comprising a compound of claim 2 and a
2 pharmaceutically acceptable carrier, diluent, or excipient.

- 1 5. A method of treatment of a cancer in a human being, the method comprising
2 administering an effective amount of the compound of claim 1 or claim 2 to a human
3 in need thereof,

4 wherein the cancer is selected from the group consisting of breast cancer,
5 endometrial cancer, brain cancer and ovary cancer.

- 1 6. The method of treatment of claim 5, wherein the cancer is breast cancer.

- 1 7. The compound of claim 2, wherein the content of compound of Formula Ib



Formula Ib

2

3 is less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less
 4 than 1%, less than 0.5%, less than 0.1, less than 0.05%, less than 0.01 % w/w or
 5 absent with respect to the compound of Formula Ia.

1 8. The compound of claim 2, wherein the enantiomeric ratio of the compound of
 2 Formula Ia is greater than 75:25, greater than 80:20, greater than 85:15, greater than
 3 90:10, greater than 95:5, greater than 99:1 or is 100:0.

1 9. The pharmaceutical composition of claim 3, wherein an amount of *S*-enantiomer of
 2 Formula I present in the composition is at least 75% of a total amount of enantiomers
 3 of Formula I present in the composition.

1 10. The pharmaceutical composition of claim 9, wherein the amount of *S*-enantiomer of
 2 Formula I present in the composition is at least 99% of the total amount of
 3 enantiomers of Formula I present in the composition.

1 11. The pharmaceutical composition of claim 10, wherein the amount of *S*-enantiomer
 2 of Formula I present in the composition is 100% of the total amount of enantiomers
 3 of Formula I present in the composition.

1 12. The compound of claim 1 or claim 2 for use in the treatment of cancer selected from
 2 breast cancer, endometrial cancer, brain cancer and ovary cancer in a human being.

1 13. The compound for use of claim 12, wherein the cancer is breast cancer.

1 14. The use of compound of claim 1 or claim 2 in the manufacture of a medicament for
 2 treating a cancer selected from a group consisting of breast cancer, endometrial
 3 cancer, brain cancer and ovary cancer in a human being.

1 15. The use of claim 14, wherein the cancer is breast cancer.